# Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

> **NCT03181815** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 48 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Relapse Leukemia

## Interventions

- **DRUG:** Cladribine
- **DRUG:** G-CSF
- **DRUG:** Aclarubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT03181815
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03181815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03181815, "Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03181815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*